FDA just approved Rasonque, the first pill designed to target the most common type of pancreatic cancer — a disease long considered untreatable. This breakthrough drug, which doubles median survival time compared to chemo and offers fewer side effects, works by using molecular glue to attack a previously “undruggable” protein. Its approval ahead of schedule signals urgency for patients, while its success may unlock new treatments for other cancers too.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
